Kazuo Kitagawa
Overview
Explore the profile of Kazuo Kitagawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
314
Citations
3658
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Quinn T, Kitagawa K, Leung T, Molina C, Rabinstein A, Bentley R, et al.
Medicine (Baltimore)
. 2025 Jan;
104(3):e41249.
PMID: 39836564
Background: A vast amount of literature is available on the burden of acute ischemic stroke (AIS). Yet, most information on AIS burden does not stratify by stroke severity, and the...
2.
Saito M, Hoshino T, Ishizuka K, Kato Y, Shibata N, Kitagawa K
J Neurosci Res
. 2024 Dec;
102(12):e70003.
PMID: 39722429
Remote ischemic conditioning (RIC) has attracted considerable attention as a brain protection strategy, although its impact remains unclear. Hypothermia is the most effective strategy in experimental transient cerebral ischemia. Therefore,...
3.
Wada S, Koga M, Kagimura T, Toyoda K, Nagai Y, Aoki S, et al.
J Neurol Sci
. 2024 Dec;
468():123342.
PMID: 39673820
Background And Aims: We aimed to investigate long-term changes in carotid intima-media thickness (IMT) based on baseline blood pressure (BP) levels in non-cardioembolic stroke patients. Methods: Patients aged 45-80 years...
4.
Ikeguchi R, Kanda N, Kobayashi M, Masui K, Nitta M, Misu T, et al.
Mult Scler J Exp Transl Clin
. 2024 Dec;
10(4):20552173241301011.
PMID: 39651331
Background: Few studies have examined B cells among patients with anti-myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), including brain pathology. Objective: To describe cases of tumefactive MOGAD with B-cell dominant...
5.
Kitagawa K
No Shinkei Geka
. 2024 Dec;
52(6):1136-1143.
PMID: 39622319
Hypertension is the most important risk factor for stroke. For both primary and secondary stroke prevention, the target blood pressure level is 130/80 mmHg in the current guidelines. Intensive blood...
6.
Hoshino T, Ishizuka K, Seki M, Hosoya M, Toi S, Mizuno T, et al.
J Atheroscler Thromb
. 2024 Dec;
PMID: 39617480
Aims: The Pemafibrate for Prevention of Atherosclerotic Diseases in Stroke (PPAR Stroke) study aimed to assess the effects of pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, on the...
7.
Maeda Y, Ikeguchi R, Masui K, Kurata A, Kitagawa K, Shimizu Y
Neuropathology
. 2024 Oct;
PMID: 39475111
Here, we report a case of antineutrophil cytoplasmic antibody (ANCA)-associated central nervous system (CNS) vasculitis that mimicked a brain tumor. The patient presented with progressive right upper arm weakness. Brain...
8.
Yokote K, Ako J, Kitagawa K, Osada N, Sheng F, Sonoda M, et al.
J Am Heart Assoc
. 2024 Oct;
13(21):e035809.
PMID: 39470058
Background: Evolocumab is the first monoclonal antibody against proprotein convertase subtilisin/kexin type 9 approved in Japan for familial hypercholesterolemia (FH) and hypercholesterolemia; however, data on its safety and effectiveness in...
9.
Morimoto R, Kitagawa K, Iijima M
J Neurol Sci
. 2024 Oct;
466:123253.
PMID: 39357293
Parkinson's disease (PD) is a neurodegenerative disorder that causes a variety of motor and non-motor symptoms (NMS), which affect the patient's quality of life (QOL). This study aimed to compare...
10.
Hosoya M, Toi S, Seki M, Hoshino T, Sato Y, Yoshizawa H, et al.
Cerebrovasc Dis
. 2024 Sep;
:1-10.
PMID: 39284290
Introduction: The primary objective of this study was to elucidate the predictive role of subtle motor impairment evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS) Part III on mortality...